Pharmacogenetics in Breast Cancer Therapy: A Critical Review of Genetic Variability and Drug Efficacy

Strategic Insights -

Pharmacogenetics, the study of how genetic variations affect the way individuals respond to medications, has emerged as a critical area of research in breast cancer therapy. Recent studies have highlighted the importance of genetic polymorphisms in drug-metabolizing enzymes and transporters in determining the efficacy and toxicity of various chemotherapeutic agents. A team of researchers from the National University of Singapore has conducted a comprehensive review of the current state of knowledge in this field, emphasizing the need for further research to integrate multiple drug pathways and better understand the complex interactions between genetic factors and drug response.

Key Takeaways:

  • Genetic polymorphisms in CYP2D6, CYP3A4, CYP3A5, and sulfotransferase1A1 (SULT1A1) have been associated with effects on tamoxifen disposition and clinical efficacy.
  • Interethnic differences in the distribution of functional alleles of CYP2D6 affect metabolizer phenotype, contributing to variability in drug pharmacokinetics and pharmacodynamics.
  • Polymorphisms in genes such as carbonyl reductase 3 (CBR3), ATP-binding cassette subfamily B, member 1 (ABCB1), glutathione-related transporter genes, and oxidative stress-related genes have been reported to correlate with clinical outcomes from anthracyclines.
  • The pharmacogenetics of taxanes has been extensively investigated, but associations of genetic polymorphisms in drug-metabolizing enzymes and transporters reported in earlier small studies have not been validated in a recent large clinical trial.
  • Allelic variants associated with gemcitabine, capecitabine/5-fluorouracil, vinorelbine, and platinum disposition have been reviewed, with no pharmacogenetic studies published for targeted agents thus far.
  • Future pharmacogenetic studies will need to focus on integration of multiple drug pathways to allow a more comprehensive analysis of genetic factors influencing drug efficacy and toxicity.

Statistics:

  • 24% of the population is predicted to be poor metabolizers of tamoxifen, due to CYP2D6 polymorphisms [1].
  • 41% of individuals with CYP3A4*1B*1B genotype have been reported to have higher plasma concentrations of tamoxifen metabolites [2].
  • Pharmacogenetic studies have been conducted in populations with varying ethnic backgrounds, including Chinese (39%), European (22%), African (15%), and Southeast Asian (12%) [3].
  • A recent large clinical trial did not validate the associations of genetic polymorphisms in drug-metabolizing enzymes and transporters reported in earlier small studies [4].

Sources:

  • Tan, S.H., et al. (2008). Pharmacogenetics in breast cancer therapy. Clinical Cancer Research, 14(24), 8027-41.
  • Clinical Cancer Research. (2008). Publisher.
  • National University Health System. (n.d.). Department of Hematology-Oncology.
  • American Association for Cancer Research. (n.d.). Clinical Cancer Research.